Product image of Ibandronat Stada (Ibandronic Acid) supplied by GNH India

Ibandronat Stada

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronat Stada (Ibandronic Acid)

Ibandronic Acid, the active ingredient in Ibandronat Stada, is a bisphosphonate presented as a tablet for oral use. It is employed to treat and prevent osteoporosis in postmenopausal women and in patients receiving glucocorticoid therapy. The drug belongs to the class of bone‑resorbing inhibitors and is marketed across the European Union.

GNH India supplies Ibandronat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution to clinical settings.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ibandronat Stada is indicated for osteoporosis and related bone‑loss conditions, acting on the skeletal remodeling pathway.
  • Postmenopausal osteoporosis: reduces risk of vertebral and hip fractures by increasing bone mineral density.
  • Glucocorticoid‑induced osteoporosis: improves bone strength and lowers fracture incidence in patients on long‑term glucocorticoid therapy.
  • Prevention of postmenopausal osteoporosis: maintains bone density to delay onset of osteoporotic fractures in at‑risk women.

How It Works

  • Ibandronic Acid binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the drug‑coated bone surface, the compound is internalized and inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. This disruption impairs prenylation of small GTP‑binding proteins, leading to reduced osteoclast activity, apoptosis, and ultimately decreased bone resorption.

Side Effects

Ibandronat Stada may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia.
  • Musculoskeletal pain: transient bone, joint or muscle aches.
  • Flu‑like symptoms: fever, chills, fatigue.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed bone and infection in the jaw area.
  • Atypical femoral fracture: low‑energy fracture of the subtrochanteric region.
  • Severe hypersensitivity: anaphylaxis or angioedema.
  • Renal impairment: acute kidney injury or worsening of pre‑existing renal disease.

Precautions & Warnings

Before prescribing Ibandronat Stada, clinicians should consider several safety measures.

  • Renal function assessment: evaluate baseline creatinine clearance before initiating therapy.
  • Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
  • Concomitant medications: review use of NSAIDs, corticosteroids, or other nephrotoxic agents.
  • Dental health: obtain dental examination and complete invasive procedures before starting treatment.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Avoid Interactions

Ibandronat Stada can interact with other medicines, requiring attention to timing and monitoring.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: reduce ibandronate absorption; separate dosing by at least 30 minutes.
  • Calcium supplements: interfere with oral bioavailability; take ibandronate at least 2 hours before calcium.
  • Renal toxic drugs (e.g., aminoglycosides, NSAIDs): increase risk of kidney injury when combined.

Moderate Interactions (Monitor Closely)

  • Warfarin: possible alteration of INR; monitor coagulation parameters.
  • Corticosteroids: additive risk of bone loss; assess bone density regularly.
  • Diuretics (thiazides): may affect calcium balance; monitor serum electrolytes.

Frequently Asked Questions

Ibandronat Stada contains Ibandronic Acid, a bisphosphonate indicated for the treatment and prevention of osteoporosis in postmenopausal women and for glucocorticoid‑induced osteoporosis. It helps increase bone mineral density and reduces the risk of vertebral and hip fractures.

Ibandronic Acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and blocks farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. This inhibition impairs osteoclast function and survival, leading to decreased bone resorption.

The dosing regimen for Ibandronat Stada is determined by the prescribing healthcare professional based on the patient’s condition, renal function, and other clinical factors. Patients should follow the specific instructions provided by their prescriber and pharmacist.

Ibandronat Stada is generally not recommended during pregnancy or lactation because safety data are limited. It should only be used if the potential benefits justify the possible risks to the fetus or infant, and this decision must be made by a qualified prescriber.

To order Ibandronat Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ibandronat Stada is a potent bisphosphonate similar to alendronate or risedronate but is often administered less frequently (e.g., monthly). Its efficacy in increasing bone density and reducing fracture risk is comparable, while the safety profile aligns with the class, featuring gastrointestinal and rare serious adverse events.

Ibandronat Stada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Ibandronat Stada is taken orally, usually on an empty stomach with a full glass of water. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during that time to ensure optimal absorption.

The most serious risks include osteonecrosis of the jaw, atypical femoral fractures, severe hypersensitivity reactions such as anaphylaxis, and acute renal impairment. Patients should be monitored for these events, especially if they have pre‑existing dental issues or kidney disease.

Ibandronat Stada is contraindicated in patients with known hypersensitivity to ibandronic acid or any excipients, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with active dental infections or untreated jaw conditions. Caution is also advised for pregnant or nursing women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT